AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index^® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market^® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market^® (NASDAQ^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December.  Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

CONTACT: uniQure: 					
         Aicha Diba 					
         Investor Relations 				
         Direct : +31 20 240 6100			
         Main: +31 20 566 7394			
         a.diba@uniQure.com				

         Media inquiries:
         Gretchen Schweitzer 
         MacDougall Biomedical Communications
         Direct: +49 172 861 8540
         Main: +49 89 2424 3494 or +1 781 235 3060
         gschweitzer@macbiocom.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.